SpinalCyte Announces Sustained 12-Month MRI Outcomes After CybroCell™ Injection
SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD).
The trial assessed patients using the Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and disc height via MRI scans. Using composite scoring, 54% of the treatment arm patients met all three endpoints as compared to only 17% with the placebo (p=0.0003). Over 84% of patients in the treatment group of CybroCell™ or CybroCell™ with platelet rich plasma (PRP) injections had an increase or no change in disc height compared to 25% for the placebo saline injection.
Analyzed individually, 83% of spinal discs that were injected with CybroCell™ had an increase or no change in disc height compared to 25% of saline injected discs. The 12-month MRI data from the landmark Phase 1/Phase 2 trial were analyzed for 17 patients by an independent radiological expert.
“Verification of structural improvements via MRI at 6- and 12-months strongly suggests that we are inducing a biological cascade of events associated with the induction of a regenerative process in the patient,” said Jesus Perez, M.D., principal investigator of the clinical trial. “Based on the clinical observations, imaging studies and patient testimonies, I believe that CybroCell™ is a breakthrough in the treatment of DDD.”
As previously reported, after 6- and 12-months, more than 90% of the treatment group had over a 10-point reduction in Oswestry Disability Index (ODI) and 100% had improvement in Visual Analogue Scale (VAS). On average, treatment group patients showed a 59% improvement in ODI scores, compared to the 22% improvement in the placebo group.
“The MRI image study demonstrates that a single injection of CybroCell™ leads to persistent structural and functional improvement in patients with DDD over a year,” said SpinalCyte Chief Scientific Officer, Thomas Ichim, Ph.D. “To my knowledge, the pain and MRI data are clearly superior to all other reported cell therapy trial data for DDD. Developing solutions which target and treat the source of chronic pain for patients with DDD, a population which today accounts for about 50% of prescription opioid usage, has implications in combating the opioid epidemic.”
SpinalCyte’s Phase 1/Phase 2 clinical trial is the first allogeneic use of fibroblasts outside of skin conditions. CybroCell™ is based on research showing that skin derived cells are capable of healing the disc as previously reported in The Spine Journal.
“There are limited options to treat the pain in patients with DDD and no treatments that can regrow the spinal disc,” said SpinalCyte Chief Executive Officer, Pete O’Heeron. “With the positive 12-month data from our trial, SpinalCyte is positioned at the forefront of this emerging sector of fibroblast-based cell therapies. In contrast to stem cells, which are difficult and costly to procure and develop into a drug, CybroCell™ uses fibroblasts which are found in large numbers and are already approved by the FDA for treatment of skin conditions. Our proprietary technology also holds promise for additional degenerative ailments including disc degeneration, cancer, diabetes, liver failure and heart failure.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
CybroCell™ is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients who were injected with CybroCell™ had sustained improvement in pain relief and increased back mobility.
Based in Houston, Texas, SpinalCyte, LLC is a regenerative medicine company developing an innovative solution for spinal disc regeneration using human dermal fibroblasts. Currently, SpinalCyte holds 35 U.S. and international issued patents and has filed for an additional 41 patents pending. SpinalCyte holds 110 U.S. and International Patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
FedEx Trade Networks Rebrands as FedEx Logistics17.1.2019 17:00 | Tiedote
FedEx Corp. (NYSE:FDX) announced today that FedEx Trade Networks, Inc. is being rebranded as FedEx Logistics. The new name describes the company’s ability to meet its customers’ increasingly complex and industry-specific supply chain, transportation, value-added services, and brokerage needs. FedEx Logistics provides specialty solutions that complete a simple, seamless and powerful global trade experience for FedEx customers around the world. “We’re adding tremendous value by bringing all of the specialty services we offer under the FedEx Logistics banner,” said Richard W. Smith, president & CEO of FedEx Logistics. “The global solutions we offer are dynamic and customizable, and the experience for our customers is more streamlined, more efficient and better represented as a collective competitive offering as FedEx Logistics. Our simplified customer interface and comprehensive ability to meet every logistics need will have a profound effect for FedEx customers, our team members, and on
French Lingerie Rocks the World!17.1.2019 16:00 | Tiedote
Following the success of its "Lingerie, Mon Amour" Show in January 2017, Promincor - Lingerie Française (Association for the Promotion of Corsetry Industries) and the DEFI (Committee of Promotion and Development for the Clothing) once again bring together leading French Lingerie brands for an exceptional Parisian Show on January 20, 2019 at 8:45 p.m. (local time), which will be live-streamed on www.lingeriefrancaise.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190117005060/en/ SHOW LINGERIE FRANÇAISE ROCKS (Photo: @lingeriefrancaise ) A true musical Show Fourteen prestigious French Lingerie brands (Antigel, Antinéa, Aubade, Chantelle, Empreinte, Eprise, Epure, Implicite, Passionata, Lise Charmel, Lou, Louisa Bracq, Maison Lejaby, Simone Pérèle) and 3 guest French designers (Badines Lingerie, Jolies Mômes and Henriette H) will present their latest collections to an audience of 600 people that include media, influencers
LTI Acquires Ruletronics, a Boutique Pega® Consulting Company17.1.2019 14:08 | Tiedote
Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company has acquired Ruletronics, a pure-play Pega® consulting and implementation company with offices in the UK, USA, and India. Ruletronics enables businesses to transform and evolve digitally by providing innovative BPM and CRM solutions leveraging Pega Platform. Their current industry strength lies across Insurance, Banking, Healthcare and Retail segments. The company offers unique product based offerings for Disability Claims management, KYC Bulk Remediation, and Insurance Sales & Service applications. The acquisition will strengthen LTI’s rapidly growing digital business with a suite of capabilities in Pega implementation space around establishing BPM Roadmap & Strategy, Customer Services, RPA and Decisioning. Nachiket Deshpande, COO, LTI, said: “Pega is a leader in Intelligent Business Process Management segment with more than 3,000 customers globally. Ruletronics brings s
Formetrix Hires CEO and Commits to New Headquarters in Greater Boston17.1.2019 14:05 | Tiedote
Formetrix, Inc., a designer and producer of proprietary, high-performance, steel alloys for additive manufacturing, has named Scott Pearson as its new Chief Executive Officer. The Company also announces that it has committed to a new headquarters in the greater Boston area with occupancy scheduled to occur in March. “We are thrilled to attract someone of Scott’s caliber and experience to lead Formetrix as we enter our next phase of growth,” said K. Leonard Judson, a Formetrix Director and the President and Managing Director of Cycad Group. Judson continued, “Scott is the ideal person to drive the Company’s growth and operational strategies, to establish mutually beneficial partnerships with industry and customers, and to establish the company as a leader in the rapidly developing additive manufacturing materials space.” “I am excited to join the Formetrix team and to lead the organization as we target the opportunities that exist in the 3D printing market today for our world-class, ste
AGCO Focuses on Animal Welfare17.1.2019 13:00 | Tiedote
AGCO (NYSE: AGCO), a global leader in manufacturing and the distribution of agricultural equipment and solutions, today hosted its annual AGCO Berlin Summit. The international industry event aims to bring together decision-makers in politics, economy and society to share their experiences and discuss the future of the agricultural industry. Today’s ‘Feeding the World - The Future for Protein’ summit was focused on aspects of animal welfare in the context of modern agriculture, including the need for sustainable protein production to meet an increasing demand for protein-rich foods. The AGCO Berlin Summit is a joint initiative of AGCO and the new AGCO Agriculture Foundation. The AGCO Agriculture Foundation develops charitable initiatives to enhance global food security, sustainable agricultural development and positive economic impacts, particularly in developing countries. As in previous years, AGCO Finance and AGCO Fuse Technologies are sponsors of the 2019 AGCO Berlin Summit. "Whilst
Mr. Paul Bridwell Joins OpenGate Capital in Senior Operations Role for North America17.1.2019 11:00 | Tiedote
OpenGate Capital, a global private equity firm, announced that Mr. Paul Bridwell joined the firm on November 5th, 2018, as Managing Director to lead operations and portfolio management for the firm’s North American-based investments. Based in Los Angeles, Bridwell joins the OpenGate senior leadership team as a member of the firm’s Investment and Portfolio Committees. Bridwell is a tenured professional with 15 years of private equity experience and has a proven track record of delivering operating results leading to superior investor returns. He possesses solid leadership and organizational skills both as portfolio company CEO and as an operations leader developed through his tenure at two global, private equity firms. Prior to joining OpenGate, Bridwell was Partner and Managing Director – Head of Operations at a major private equity investment firm in New York City, where he established the firm’s first operations-focused group and developed a comprehensive operations approach compatib
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme